ArticlePharmacological research2020
Angiotensin receptor blockers and COVID-19.
Article in Pharmacological research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 56 citations in OpenAlex.
- Role of endothelial dysfunction in the severity of COVID‑19 infection (Review).Molecular medicine reports · 2022Review
- Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?Pharmaceuticals (Basel, Switzerland) · 2022Review
- Acute and Long-Term Consequences of COVID-19 on Arterial Stiffness-A Narrative Review.Life (Basel, Switzerland) · 2022Review
- Carbohydrate Ligands for COVID-19 Spike Proteins.Viruses · 2022Article
- SARS-CoV-2 Infectivity and Neurological Targets in the Brain.Cellular and molecular neurobiology · 2022Article
- COVID-19, ferrosenescence and neurodegeneration, a mini-review.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19.Medical hypotheses · 2021Article
- Impact of Arterial Stiffness on All-Cause Mortality in Patients Hospitalized With COVID-19 in Spain.Hypertension (Dallas, Tex. : 1979) · 2021Observational
- Article
- COVID-19 and Cardiovascular Diseases.Advances in experimental medicine and biology · 2021Article
- COVID-19 in Patients with Hypertension.Advances in experimental medicine and biology · 2021Article
- Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials.Frontiers in pharmacology · 2021Article
- Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19.Frontiers in medicine · 2021Review
- Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study.Cardiovascular diabetology · 2020Article
- Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.Toxicology and applied pharmacology · 2020Article
- COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients.Journal of the American Medical Directors Association · 2020Observational
- Candesartan could ameliorate the COVID-19 cytokine storm.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Article
- Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients.Cell discovery · 2020Article
- Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19.Journal of clinical medicine · 2020Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current COVID-19 pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.